{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:18:56Z","timestamp":1778617136618,"version":"3.51.4"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,2]]},"DOI":"10.18632\/oncotarget.11425","type":"journal-article","created":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T06:30:40Z","timestamp":1471674640000},"page":"29679-29698","source":"Crossref","is-referenced-by-count":9,"title":["CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia"],"prefix":"10.18632","volume":"8","author":[{"given":"Borja","family":"Guerra","sequence":"first","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epa\u00f1a"},{"name":"Unidad de Apoyo a la Docencia en Enfermer\u00eda-Fuerteventura, Universidad de Las Palmas de Gran Canaria, Espa\u00f1a"},{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Mart\u00edn-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"D\u00edaz-Chico","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epa\u00f1a"},{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"McNaughton-Smith","sequence":"additional","affiliation":[{"name":"Centro Atl\u00e1ntico del Medicamento, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Jim\u00e9nez-Alonso","sequence":"additional","affiliation":[{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"},{"name":"Departamento de Qu\u00edmica Org\u00e1nica, Instituto de Bio-Org\u00e1nica Antonio Gonz\u00e1lez, Universidad de la Laguna, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idaira","family":"Hueso-Falc\u00f3n","sequence":"additional","affiliation":[{"name":"Centro Atl\u00e1ntico del Medicamento, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Montero","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer, CSIC, Universidad de Salamanca, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Blanco","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina y Biotecnolog\u00eda de Cantabria, CSIC-Universidad de Cantabria, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Le\u00f3n","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina y Biotecnolog\u00eda de Cantabria, CSIC-Universidad de Cantabria, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Centro Atl\u00e1ntico del Medicamento, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Est\u00e9vez-Braun","sequence":"additional","affiliation":[{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"},{"name":"Departamento de Qu\u00edmica Org\u00e1nica, Instituto de Bio-Org\u00e1nica Antonio Gonz\u00e1lez, Universidad de la Laguna, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atanasio","family":"Pandiella","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer, CSIC, Universidad de Salamanca, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonifacio Nicol\u00e1s","family":"D\u00edaz-Chico","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epa\u00f1a"},{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"},{"name":"Centro Atl\u00e1ntico del Medicamento, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Fern\u00e1ndez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epa\u00f1a"},{"name":"Instituto Canario de Investigaci\u00f3n sobre el C\u00e1ncer, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Sexl","year":"2012","journal-title":"Nat Chem Biol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Holyoake","year":"2013","journal-title":"Br J Pharmacol"},{"key":"4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/onc.2009.374","article-title":"Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR\/p70S6-kinase pathway","volume":"29","author":"Fischer","year":"2010","journal-title":"Oncogene"},{"key":"5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Sexl","year":"2013","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cellsand","volume":"124","author":"Holyoake","year":"2014","journal-title":"Blood"},{"key":"7","first-page":"75","article-title":"Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr\/Abl kinase activity","volume":"54","author":"Goolsby","year":"2003","journal-title":"Cytometry A"},{"key":"8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML","volume":"6","author":"Cortes","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Egger","year":"2011","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Cortes","year":"2009","journal-title":"Cancer Control"},{"key":"11","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.4161\/cc.10.23.18323","article-title":"Mechanism of action of the multikinase inhibitor Foretinib","volume":"10","author":"Auberger","year":"2011","journal-title":"Cell Cycle"},{"key":"12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.12308","article-title":"Inhibition of related JAK\/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm","volume":"161","author":"Martinez-Lopez","year":"2013","journal-title":"Br J Haematol"},{"key":"13","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.18632\/oncotarget.2465","article-title":"Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia","volume":"5","author":"Moriggl","year":"2014","journal-title":"Oncotarget"},{"key":"14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/leu.2014.156","article-title":"Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia","volume":"29","author":"White","year":"2015","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-pharmtox-010611-134517","article-title":"The chemical biology of naphthoquinones and its environmental implications","volume":"52","author":"Cho","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"16","doi-asserted-by":"crossref","first-page":"20309","DOI":"10.1039\/C4RA13547D","article-title":"Understanding cancer and the anticancer activities of naphthoquinones - a review","volume":"5","author":"Wellington","year":"2015","journal-title":"RSC Advances"},{"key":"17","unstructured":"McNaughton, Est\u00e9vez-Braun, Jim\u00e9nez-Alonso, Guti\u00e9rrez-Ravelo, Fern\u00e1ndez-P\u00e9rez, Diaz-Chico. Fused quinonic compounds. International (US-E) patent. Patent WO2014016314 A1. 2014 Jan 30."},{"key":"18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","article-title":"Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance","volume":"53","author":"Levitzki","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.onc.1205229","article-title":"Cdc25C interacts with PCNA at G2\/M transition","volume":"21","author":"Okamoto","year":"2002","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Grant","year":"2010","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Korsmeyer","year":"2004","journal-title":"Cell"},{"key":"22","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Moriggl","year":"2005","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","article-title":"Small molecule Mcl-1 inhibitors for the treatment of cancer","volume":"145","author":"Fesik","year":"2015","journal-title":"Pharmacol Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.V93.7.2369","article-title":"Constitutive activation of the JAK2\/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines","volume":"93","author":"Zuckerman","year":"1999","journal-title":"Blood"},{"key":"25","first-page":"1178","article-title":"Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone","volume":"44","author":"Paterson","year":"1984","journal-title":"Cancer Res"},{"key":"26","first-page":"383","article-title":"Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells","volume":"61","author":"Hynes","year":"2001","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Sawyers","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ong","year":"2003","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"23875","DOI":"10.1074\/jbc.M112.445148","article-title":"Inhibition of protein synthesis alters protein degradation through activation of protein kinase B (AKT)","volume":"288","author":"Gong","year":"2013","journal-title":"J Biol Chem"},{"key":"30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u201cde novo\u201d resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"Moreno Gimeno","year":"2009","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib","volume":"9","author":"Leon","year":"2011","journal-title":"Mol Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1182\/blood-2008-09-177774","article-title":"Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks","volume":"113","author":"Avil\u00e9s","year":"2009","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/cr.2008.86","article-title":"Induction of apoptosis by shikonin through a ROS\/JNK-mediated process in Bcr\/Abl-positive chronic myelogenous leukemia (CML) cells","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.leukres.2011.06.018","article-title":"Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression","volume":"35","author":"McKallip","year":"2011","journal-title":"Leuk Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Costa","year":"2011","journal-title":"Invest New Drugs"},{"key":"37","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor:assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"38","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1074\/jbc.M114.616748","article-title":"A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells","volume":"290","author":"Lin","year":"2015","journal-title":"J Biol Chem"},{"key":"39","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Lillie","year":"2010","journal-title":"J Med Chem"},{"key":"40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canlet.2015.01.021","article-title":"The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6","volume":"359","author":"Wanx","year":"2015","journal-title":"Cancer Lett"},{"key":"41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Arlinghaus","year":"2011","journal-title":"Leukemia"},{"key":"42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1535-7163.MCT-13-0629","article-title":"MCL-1 degradation mediated by JNK activation via MEKK1\/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189","volume":"13","author":"Miao","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Fernandez-Luna","year":"2000","journal-title":"J Exp Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrm2153","article-title":"The apoptosome: signalling platform of cell death","volume":"8","author":"Salvesen","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/excr.2000.4836","article-title":"Serine\/threonine protein kinases and apoptosis","volume":"256","author":"Lord","year":"2000","journal-title":"Exp Cell Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Han","year":"2005","journal-title":"Cell Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3892\/or.2013.2331","article-title":"Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells","volume":"29","author":"Lin","year":"2013","journal-title":"Oncol Rep"},{"key":"48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1476-4598-4-43","article-title":"Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells","volume":"4","author":"Ip","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"49","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"Lukas","year":"2007","journal-title":"Oncogene"},{"key":"50","doi-asserted-by":"crossref","first-page":"18414","DOI":"10.3390\/molecules191118414","article-title":"Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia\u2014the possibility to target several kinases through inhibition of the various CDC25 isoforms","volume":"19","author":"Bruserud","year":"2014","journal-title":"Molecules"},{"key":"51","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1074\/jbc.274.21.14791","article-title":"Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling","volume":"274","author":"Ross","year":"1999","journal-title":"J Biol Chem"},{"key":"52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1023\/A:1008915305681","article-title":"Positively charged polymer polylysine-induced cell adhesion molecule redistribution in K562 cells","volume":"9","author":"Santini","year":"1998","journal-title":"J Mater Sci Mater Med"},{"key":"54","doi-asserted-by":"crossref","first-page":"31408","DOI":"10.1074\/jbc.273.47.31408","article-title":"Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes","volume":"273","author":"Fishman","year":"1998","journal-title":"J Biol Chem"},{"key":"55","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-13-3044","article-title":"NADPH oxidases as therapeutic targets in chronic myelogenous leukemia","volume":"20","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1152\/japplphysiol.00805.2010","article-title":"Is sprint exercise a leptin signaling mimetic in human skeletal muscle?","volume":"111","author":"Calbet","year":"2011","journal-title":"J Appl Physiol (1985)"},{"key":"57","doi-asserted-by":"crossref","first-page":"e96305","DOI":"10.1371\/journal.pone.0096305","article-title":"Lipid profiling and transcriptomic analysis reveals a functional interplay between estradiol and growth hormone in liver","volume":"9","author":"Diaz","year":"2014","journal-title":"PLoS One"},{"key":"58","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"59","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume":"132","author":"Skaletsky","year":"2000","journal-title":"Methods Mol Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:20:13Z","timestamp":1594830013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,19]]},"references-count":59,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,5,2]]}},"alternative-id":["11425","27557509"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11425","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,19]]}}}